RT Journal Article
SR Electronic
T1 Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over Long Time Period
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.13.22277579
DO 10.1101/2022.07.13.22277579
A1 Dagher, Hiba
A1 Chaftari, Anne-Marie
A1 Subbiah, Ishwaria M.
A1 Malek, Alexandre E.
A1 Jiang, Ying
A1 Lamie, Peter
A1 Granwehr, Bruno
A1 John, Teny
A1 Yepez, Eduardo
A1 Borjan, Jovan
A1 Reyes, Cielito
A1 Flores, Mary
A1 Khawaja, Fareed
A1 Pande, Mala
A1 Ali, Noman
A1 Rojo, Raniv
A1 Karp, Daniel D.
A1 Hachem, Ray
A1 Raad, Issam
YR 2022
UL http://medrxiv.org/content/early/2022/07/15/2022.07.13.22277579.abstract
AB Background An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The long-term consequences of COVID-19 are not fully understood particularly in the cancer patient population. The purpose of this study is to assess post-acute sequelae of SARS-CoV-2 infection (PASC) in cancer patients following acute COVID-19 recovery.Methods We identified cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-19 disease between March 1, 2020 and Sept 1, 2020 and followed them till May 2021. To assess PASC, we collected patients reported outcomes through questionnaires that were sent to patients daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. We also reviewed patients’ electronic medical records to capture the the persistence or emergence of new COVID19-related symptoms reported during any clinic or hospital encounter beyond 30 days of the acute illness and up to 14 months.Results We included 312 cancer patients with a median age of 57 years (18-86). The majority of patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis. The most common symptoms reported included fatigue (82%), sleep disturbances (78%), myalgias (67%) and gastrointestinal symptoms (61%), followed by headache, altered smell or taste, dyspnea (47%) and cough (46%). A higher number of females reported a persistence of symptoms compared to males (63% vs 37%; p=0.036). Cancer type, neutropenia, lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in both groups. Among the 188 patients with PASC, only 16 (8.5%) were readmitted for COVID-related reasons.Conclusions More than one out of two cancer patients, and more likely females, report PASC that may persist beyond 6 months and even one year. The most common symptoms are non-respiratory and consist of fatigue, sleep disturbance, myalgia and gastro-intestinal symptoms. Most of the cancer patients with PASC were managed on outpatient basis with only 8,5% requiring a COVID-19 related re-admission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672, which supports MD Anderson Cancer Center's Clinical Trials Office.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study was approved by the Institutional Review Board of MD Anderson Cancer Center, and a waiver of informed consent was obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThese are human subjects of multicenter trials and we are unable to share data because of IRB restrictions from different sites in different countries. The study protocol, statistical analysis plan, lists of deidentified individual data, generated tables and figures will be made available upon request by qualified scientific and medical researchers for legitimate research purposes. Requests should be sent to achaftari{at}mdanderson.org and yijiang{at}mdanderson.org. Data will be available on request for 6 months from the date of publication. Investigators are invited to submit study proposal requests detailing research questions and hypotheses in order to receive access to these data. The software we used for data analysis is SAS version 9.3 (SAS Institute Inc., Cary, NC), and we have provided this information in Statistical analysis section of the manuscript.